Combinations; 1. Diosmin / Hesperidin
Dosage ; CVI: 2 OD (morning or evening) or 1BD.
HD: Acute episode: 6 tabs daily for 4 days, followed by 4 tabs daily for 3 days.
Prevention of recurrence: 2 tabs daily for a minimum of 3 months
Diosmin Brands (semi Synthetic);
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Phlebodia | Innotech | 600mg | 15s | KES 770 |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Daflon | Servier | 450mg/50mg | 50s | Tablets | KES
710 |
|
Diosmin / Hesperidin (Semi Synthetic)Brands
Diosmin / Hesperidin more info |
|||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mode Of Action | Vascular protectors and venotonic that act on the return vascular system reducing venous distensibility and venous stasis. They also normalize capillary permeability besides reinforcing capillary resistance. |
||||||||||||||||||||||||
| Drug Indication | Organic and idiopathic venous diseases such as chronic venous insufficiency (CVI) of the lower limbs with symptoms that include heavy legs; pain; nocturnal cramps; haemorrhoidal disease. | ||||||||||||||||||||||||
| Side Effects | It is generally well tolerated, including in pregnancy, with a lower or identical rate of side effects as placebo. Mild GI symptoms such as nausea and gastric discomfort or mild autonomic symptoms such as headache and vertigo | ||||||||||||||||||||||||
| Dosage | CVI: 2 OD (morning or evening) or 1BD.HD: Acute episode: 6 tabs daily for 4 days, followed by 4 tabs daily for 3 days. Prevention of recurrence: 2 tabs daily for a minimum of 3 months. | ||||||||||||||||||||||||
| Special Information | Micronized Purified Flavonoid Fraction, MPFF, is an improved diosmin/hesperidin formulation in which the particles of active substance are micronized to particle sizes of less than 1.7 in comparison to an average size of 37 for non-micronized diosmin.This increases the rate of GI absorption of the active substance by 52% resulting in a gain in clinical efficacy of 30% in terms of improvement of symptoms | ||||||||||||||||||||||||
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM | ||||||||||||||||||||||||
| Drug Sub-Category | Phlebotropic agents | ||||||||||||||||||||||||